Clinical Trial Update: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for durvalumab plus CV301 with maintenance chemotherapy in metastatic colorectal or pancreatic adenocarcinoma; study status is terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma
• Colorectal Cancer
• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• CV301 (CV301 vaccine)
• Durvalumab (durvalumab)

Snippet

Sponsor: Georgetown University | Conditions: Metastatic Colorectal Cancer, Colorectal Adenocarcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-01-10